ImmunityBio, Inc.
Regulated industryPhysical productsSells to businessesTags from an AI model reading the company description.
Key Metrics
- Previous Close
- $6.26
- 52-Week Range
- $1.95 – $12.43
- Market Cap
- $7.13B
- P/E (TTM)
- —
- EPS (TTM)
- -1.06
- Dividend Yield
- 0.00%
Advanced Metrics
- Price/Book
- —
- PEG Ratio
- —
- Return on Equity
- —
- Return on Assets
- -30.37%
- Gross Margin
- 98.79%
- Operating Margin
- -150.16%
- Profit Margin
- 0.00%
- Current Ratio
- 4.27
- Debt/Equity
- —
- Total Debt
- $1.30B
- Free Cash Flow
- $-176.33M
- Revenue Growth
- 52.30%
- Earnings Growth
- —
- Enterprise Value
- $8.09B
Market Snapshot
About
ImmunityBio is a late-stage biotechnology company developing therapies and vaccines to fight cancer and infectious diseases by amplifying both natural killer cell and T cell responses. The company's lead immunotherapy candidate, Anktiva (N-803), is an IL-15 superagonist designed to activate the body's immune system. ImmunityBio has received FDA approval for Anktiva in combination with BCG for BCG-unresponsive non-muscle invasive bladder cancer and is evaluating it in multiple other cancer indications. The company also developed a COVID-19 vaccine and is advancing cell therapy programs through its subsidiary NantKwest.